A new horizon in the treatment of serious diseases caused by epithelial injuryLearn about our Science

About Cytoki Pharma

Cytoki Pharma is a biotechnology company focused on serious diseases caused by epithelial injury with unmet medical need. The company was founded in 2019 after licensing of a full IL-22 analogue program from Novo Nordisk. We are on track to start Phase 1 for our long-acting lipidated IL-22 in late 2022 enabled by a $45 M series A from a syndicate of strong international investors, providing funding all the way to clinical proof-of-concept.

Learn about Cytoki